EMEA-001214-PIP08-21

Key facts

Invented name
Fasenra
Active substance
Benralizumab
Therapeutic area
Pneumology-allergology
Decision number
P/0497/2021
PIP number
EMEA-001214-PIP08-21
Pharmaceutical form(s)
  • Age-appropriate dosage form for parenteral use
  • Solution for injection
Condition(s) / indication(s)
Treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype
Route(s) of administration
Subcutaneous use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel.  +46 855326000
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating